-

Atlassian Corporation (TEAM) Shareholder Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Atlassian Corporation

SAN DIEGO--(BUSINESS WIRE)--The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all purchasers of Atlassian Corporation (NASDAQ: TEAM) ordinary shares and/or common stock between August 5, 2022 and November 3, 2022, for violations of the Securities Act of 1934. Atlassian develops and sells collaboration and project-management software that operates both on premises and in the cloud.

What Now: Similarly situated shareholders may be eligible to participate in the class action against Atlassian. Shareholders who want to act as lead plaintiff for the class must file their papers by April 4, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

What is this Case About: Atlassian Corporation (TEAM) Misled Investors Regarding the Company's Financial Viability and Business Prospects

According to the complaint, leading up to the class period, defendants touted the Company's financial viability. After markets closed on August 4, 2022, defendant Co-Chief Executive Officer Scott Farquhar reiterated the Company’s guidance of 50% year-on-year cloud growth for fiscal years 2023 and 2024. In a call with analysts that day, defendant and Chief Revenue Officer Cameron Deatsch assured investors the Company was “being exceedingly vigilant watching all stages of our funnel” and that “we have yet to see any specific trend . . . that gives us pause or worry to date.” According to CRO Deatsch, the “demand for collaboration products continue[s] to be strong.”

In reality, Atlassian overstated its financial guidance by concealing trends of slowing conversions from free users to paying customers and slowing growth in paying-user expansion. As a result, defendants’ positive statements about the Company’s business, operations, and prospects during the class period were materially false and /or misleading.

On November 3, 2022, Atlassian issued a letter to shareholders and held a conference call with analysts to discuss its financial results for the fiscal first quarter of 2023 ended September 30, 2022. In the letter to shareholders, defendants revealed that “[b]ased on the macro headwinds,” the Company was “lowering our Cloud revenue growth outlook to a range of approximately 40% to 45% year-over-year” for fiscal year 2023. In describing the “macro impacts” on the Company, the letter to shareholders revealed that (1) the Company “saw a decrease in the rate of Free instances converting to paid plans,” calling it a “trend [that] became more pronounced” in the quarter and (2) the Company experienced “a slowing in the rate of paid user growth from existing customers.” In response to these revelations, the price of Atlassian stock declined almost 29% the following trading day, from a closing price of $174.17 per share on November 3, 2022 to a closing price of $123.73 per share on November 4, 2022. More than $7 billion in shareholder value evaporated. Analysts reported being “surprised by the magnitude of the slowdown” as defendants “delivered unusually disappointing” results.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Atlassian Corporation settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:TEAM

Release Summary
Atlassian Corporation (TEAM) Misled Investors Regarding the Company's Financial Viability and Business Prospects
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

PNR Stockholders Have Rights – If You Lost Money Investing in Pentair plc Contact Robbins LLP for Information About Recovering Your Losses

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Pentair plc (NYSE: PNR) securities between April 28, 2026 and July 14, 2026 (the "Class Period"). Pentair provides various water solutions, such as filtration, water supply pumps, and fluid treatment products. The lawsuit alleges that Pentair misled investors regarding the destocking of its inventory in the Pool channe...

Robbins LLP Urges HDB Stockholders Who Lost Money Investing in HDFC Bank Limited to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired HDFC Bank Limited (NYSE: HDB) securities between July 17, 2023 and May 26, 2026 (the "Class Period"). HDFC is an Indian financial services conglomerate and banking company headquartered in Mumbai. The complaint alleges that HDFC Bank camouflaged payments as marketing spend to pay higher interest to a state f...

Robbins LLP Urges REPL Stockholders to Contact the Firm for Information About the Class Action Against Replimune Group, Inc.

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026 ("Class Period"). Replimune purports to be a clinical-stage biotechnology company focused on novel oncolytic immunotherapies. According to the complaint, the Company’s lead product candidate is RP1 (vusolimogene oderp...
Back to Newsroom